| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/15/2011 | US20110223148 Therapeutic/prophylactic agent for prostate cancer |
| 09/15/2011 | US20110223146 Methods for preparation and use of marrow infiltratng lymphoctyes (mils) |
| 09/15/2011 | US20110223138 Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins |
| 09/15/2011 | US20110223136 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 09/15/2011 | US20110223133 Therapeutic agent for hematopoietic tumors |
| 09/15/2011 | US20110223130 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE |
| 09/15/2011 | US20110223129 Chimeric immunoreceptor useful in treating human cancers |
| 09/15/2011 | US20110223128 Regulation of microvasculature occlusion |
| 09/15/2011 | US20110223127 SDF-1 Binding Nucleic Acids And The Use Thereof |
| 09/15/2011 | US20110223112 Unsaturated polyester coated magnetic ultra-fine particles for biological applications |
| 09/15/2011 | US20110223107 Antibodies that specifically block the biological activity of a tumor antigen |
| 09/15/2011 | US20110223105 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis |
| 09/15/2011 | US20110223102 Multimodality agents for tumor imaging and therapy |
| 09/15/2011 | US20110220265 Preparation for External Use |
| 09/15/2011 | DE102010006245A1 Herstellung und Verwendung antibakterieller, antiproliferativer und antiphytopathogener Benzanthrine Production and use antibacterial, anti-proliferative and antiphytopathogenic Benzanthrine |
| 09/15/2011 | CA2792872A1 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| 09/15/2011 | CA2792852A1 Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 09/15/2011 | CA2792769A1 Imidazopyridines syk inhibitors |
| 09/15/2011 | CA2792754A1 .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| 09/15/2011 | CA2792722A1 Phytocannabinoids in the treatment of cancer |
| 09/15/2011 | CA2792667A1 Sparc angiogenic domain and methods of use |
| 09/15/2011 | CA2792613A1 Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase |
| 09/15/2011 | CA2792327A1 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 09/15/2011 | CA2791988A1 A novel method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer |
| 09/15/2011 | CA2791693A1 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 09/15/2011 | CA2791399A1 Carbohydrate-polyamino acid-drug conjugates |
| 09/15/2011 | CA2790240A1 Use of tigecycline for treatment of cancer |
| 09/15/2011 | CA2789484A1 Cdc7 kinase inhibitors and uses thereof |
| 09/15/2011 | CA2789440A1 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| 09/14/2011 | EP2365094A1 Antisense modulation of PTP1B expression |
| 09/14/2011 | EP2365085A1 Growth hormone fusion protein |
| 09/14/2011 | EP2365081A2 13 Transmembrane protein expressed in prostate cancer |
| 09/14/2011 | EP2365075A1 Method for inhibiting the expression of a target gene and medicine for treating a tumour illness |
| 09/14/2011 | EP2365006A2 Novel anti-IGF-IR antibodies and uses thereof |
| 09/14/2011 | EP2365005A2 Novel anti-IGF-IR antibodies and uses thereof |
| 09/14/2011 | EP2365004A2 Membrane associated tumor endothelium markers |
| 09/14/2011 | EP2365003A1 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 09/14/2011 | EP2365001A2 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 09/14/2011 | EP2364997A2 Polypeptide variants with altered effector function |
| 09/14/2011 | EP2364990A1 Modulators of pharmacological agents |
| 09/14/2011 | EP2364982A1 Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
| 09/14/2011 | EP2364981A1 Salts and crystalline forms of 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 09/14/2011 | EP2364974A1 N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors |
| 09/14/2011 | EP2364973A1 Heterocyclic inhibitors of MEK and Methods of use thereof |
| 09/14/2011 | EP2364969A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/14/2011 | EP2364968A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/14/2011 | EP2364731A2 Methods of administering anti-TNFalpha antibodies |
| 09/14/2011 | EP2364728A1 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
| 09/14/2011 | EP2364727A2 Molecular antigen array |
| 09/14/2011 | EP2364719A1 Prevention and treatment of amyloidogenic diseases |
| 09/14/2011 | EP2364710A1 Therapeutic use of D-allose |
| 09/14/2011 | EP2364699A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 09/14/2011 | EP2364314A1 Modulators of toll-like receptors |
| 09/14/2011 | EP2364304A1 Alpha-lipoic acid derivatives and their use in drug preparation |
| 09/14/2011 | EP2364299A1 Bis [o-(14-benzoylaconine-8-yl)]esters |
| 09/14/2011 | EP2364185A1 Disubstituted phthalazine hedgehog pathway antagonists |
| 09/14/2011 | EP2364166A1 Suppression of cancer |
| 09/14/2011 | EP2364162A2 Compositions and methods for diagnosing and treating b-cll |
| 09/14/2011 | EP2364152A2 Methods for preparation and use of marrow infiltrating lymphocytes (mils) |
| 09/14/2011 | EP2364149A1 Tnik inhibitor and the use |
| 09/14/2011 | EP2364148A1 Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer |
| 09/14/2011 | EP2364082A1 Naphthamides as anticancer agents |
| 09/14/2011 | EP2301580A9 Container holding anti-VEGF antibodies |
| 09/14/2011 | EP2235017B1 Spiroindolinone derivatives as anticancer agents |
| 09/14/2011 | EP2231636B1 Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| 09/14/2011 | EP2225241B1 Derivatives of N-phenyl-imidazo-(1,2-A)-pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/14/2011 | EP2201001B1 Novel imidazole derivatives |
| 09/14/2011 | EP2139892B1 Substituted pyrimidodiazepines useful as plk1 inhibitors |
| 09/14/2011 | EP2049501B1 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| 09/14/2011 | EP2041140B1 Aziridinyl-epothilone compounds |
| 09/14/2011 | EP2007380B1 Use of a kinase inhibitor for the treatment of particular resistant tumors |
| 09/14/2011 | EP1948663B1 Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
| 09/14/2011 | EP1948242B1 Cytotoxic compounds |
| 09/14/2011 | EP1893211B1 Use of sanglifehrin in hcv |
| 09/14/2011 | EP1874769B1 Novel aza- heterocycles serving as kinase inhibitors |
| 09/14/2011 | EP1844815B1 Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| 09/14/2011 | EP1747777B1 Medicinal agent |
| 09/14/2011 | EP1727820B1 Amine derivatives with tyrosinkinase inhibiting activity |
| 09/14/2011 | EP1689387B1 Bicyclic inhibitors of mek and methods of synthesis thereof |
| 09/14/2011 | EP1446401B1 C5-modified indazolylpyrrolotriazines |
| 09/14/2011 | EP1445264B1 Substance specific to pd-1 |
| 09/14/2011 | EP1441766B1 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 09/14/2011 | EP1377551B1 Antiproliferative agents |
| 09/14/2011 | EP1346982B1 Vla-4 inhibitors |
| 09/14/2011 | EP1262555B1 Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells |
| 09/14/2011 | EP1257264B1 Estrogen receptor modulators |
| 09/14/2011 | EP1027440B2 Inhibitor protein of the wnt signal pathway |
| 09/14/2011 | CN1933851B Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 09/14/2011 | CN1872879B Anagonism active polypeptide of CXCR4 acceptor from inflammation protein of virus macrophage |
| 09/14/2011 | CN1842329B Preventive or ameliorating agent for liver disease involving hepatopathy |
| 09/14/2011 | CN1642551B Inhibitors of histone deacetylase |
| 09/14/2011 | CN1561345B Antibodies to VLA-1 |
| 09/14/2011 | CN1436191B Antitumoral ecteinascidin derivatives |
| 09/14/2011 | CN102186977A Inhbb epitope peptides and vaccines containing the same |
| 09/14/2011 | CN102186856A Pyrrolopyrimidine compounds as cdk inhibitors |
| 09/14/2011 | CN102186855A Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| 09/14/2011 | CN102186853A Alpha helix mimetics in the treatment of cancer |
| 09/14/2011 | CN102186852A 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 09/14/2011 | CN102186850A Phenanthroindolizidine derivative and nfkb inhibitor containing same as active ingredient |
| 09/14/2011 | CN102186849A Phenanthroindolizidine compound and nf?b inhibitor containing same as active ingredient |